Brivanib alaninate
As of the edition of 20 October 2026, Brivanib alaninate is a small molecule: stopped in 2022; acts on FGFR1, FGFR2 and FGFR3 and 4 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2022
- Kind
- Small molecule
- Registered trials
- 7, 3 stopped early
- Disease areas
- Cancer; Pregnancy and women's health; Urinary and reproductive; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product4 company-target rows are on route A because of Brivanib alaninate.
See the 4 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| FGFR1 | Fibroblast growth factor receptor 1 | P11362 |
| FLT1 | Vascular endothelial growth factor receptor 1 | P17948 |
| FGFR2 | Fibroblast growth factor receptor 2 | P21802 |
| FGFR4 | Fibroblast growth factor receptor 4 | P22455 |
| FGFR3 | Fibroblast growth factor receptor 3 | P22607 |
| FLT4 | Vascular endothelial growth factor receptor 3 | P35916 |
| KDR | Vascular endothelial growth factor receptor 2 | P35968 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 2 | 0 | 1 |
| Phase 2 | 4 | 2 | 0 | 2 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Lead sponsor of trials | 2004 to now |
| Zai Lab | Lead sponsor of trials | 2020 to now |